Ellen Blanc

Temsirolimus and bevacizumab, or sunitinib, or interferon alfa and bevacizumab for patients with advanced renal cell carcinoma (TORAVA): a randomised phase 2 trial

Sylvie Négrier, Gwénaëlle Gravis, David Pérol et al. · The Lancet Oncology · 2011 · 238 citations

Medicine, Oncology, Pharmacotherapy +9

A Phase II Trial of Sunitinib in Patients With Renal Cell Cancer and Untreated Brain Metastases

Christine Chevreau, Alain Ravaud, Bernard Escudier et al. · Clinical Genitourinary Cancer · 2013 · 81 citations

Medicine, Oncology, Pharmacology +16

Axitinib in first-line for patients with metastatic papillary renal cell carcinoma: Results of the multicentre, open-label, single-arm, phase II AXIPAP trial

Sylvie Négrier, Céline Ferlay, Marine Gross‐Goupil et al. · European Journal of Cancer · 2020 · 59 citations

Medicine, Oncology, Pharmacology +12

Can the combination of temsirolimus and bevacizumab improve the treatment of metastatic renal cell carcinoma (mRCC)? Results of the randomized TORAVA phase II trial.

B. Escudier, Sylvie Négrier, Gwénaëlle Gravis et al. · Journal of Clinical Oncology · 2010 · 52 citations

Medicine, Oncology, Pharmacology +15

The tyrosine-kinase inhibitor sunitinib targets vascular endothelial (VE)-cadherin: a marker of response to antitumoural treatment in metastatic renal cell carcinoma

Helena Polena, Julie Creuzet, Maeva Dufies et al. · British Journal of Cancer · 2018 · 33 citations · Full text

Medicine, Oncology, Pharmacology +17